Next-Generation Sequencing and Targets in Early-Phase Colorectal Cancer Drug Development
Автор: OncoDaily TV
Загружено: 2024-12-22
Просмотров: 186
Описание:
In the inaugural event of the Global Cancer Movement, initiated by OncoDaily, Dr. Vivek Subbiah delves into the revolutionary advancements in colorectal cancer care. This virtual event brings together experts to explore the transformative role of precision oncology, from molecular diagnostics like NGS (next-generation sequencing) to the rise of tissue-agnostic therapies.
Dr. Subbiah emphasizes how precision oncology is offering new hope for patients, driving improvements in treatment outcomes and redefining cancer care. This session is a must-watch for anyone keen on the latest innovations in oncology.
Don’t miss this insightful discussion from the inaugural Global Cancer Movement virtual event!
@SarahCannonResearchInstitute
SUBSCRIBE to get the latest #oncodaily / @oncodailytv
Visit the OncoDaily Website : https://oncodaily.com
Like OncoDaily on LinkedIn: / oncodaily
Like OncoDaily on X (Twitter): https://x.com/oncodaily
Follow OncoDaily on Instagram: / oncodailynews
Follow OncoDaily on TikTok: / oncodaily
Like OncoDaily on Facebook: / oncodaily
SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter
About OncoDaily
OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of #OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”
Targeted therapies for colorectal cancer are changing clinical outcomes. Learn how #moleculartesting guides specific treatment plans.
This presentation examines the latest advancements in oncology, specifically focusing on targeted therapies for #colorectalcancer patients. We review current drug regimens, including the use of Encorafenib and Cetuximab for BRAF-mutant cases, as well as the application of Larotrectinib and Entrectinib for NTRK fusions. By understanding how these specific agents interact with molecular markers, clinicians and patients can better navigate complex treatment landscapes.
Beyond current standards, the discussion covers HER2-targeting agents and the potential of antibody drug conjugates. We also analyze the necessity of comprehensive molecular testing to identify appropriate candidates for these therapies and discuss ongoing studies aiming for earlier intervention. This overview provides a clear look at how targeted therapies for colorectal cancer are evolving to improve patient management.
Subscribe for weekly oncology treatment breakdowns and comment below if you would like to see a specific cancer type covered next.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: